Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 06:48 AM
November 2025
Join Lindsay Yoder, PA-C from Indiana University, for a practical walkthrough on how to evaluate and manage autoimmune hepatitis (AIH). This concise session covers key clinical clues, diagnostic criteria, common patient questions, and real-world approaches to treatment—from steroids and azathioprine to mycophenolate, tacrolimus, and emerging steroid-sparing strategies. Learn how to recognize AIH presentations, set realistic expectations for biochemical remission, manage intolerance and relapse, and tailor long-term therapy for better outcomes. A quick, high-yield guide for clinicians looking to strengthen their approach to autoimmune hepatitis.
Related Webcast
Webcast: MASLD vs MetALD With Lavinia Iordache
September 2025
In this MASLD Community Network session, Lavinia Iordache, PA-C, clarifies the new SLD nomenclature and the distinctions between MASLD and MetALD, then walks through a real-world case (Ashley, 52) to show how to quantify alcohol intake, recognize cardiometabolic risk factors, and stage disease using non-invasive tests (FIB-4, FibroScan/VCTE with CAP, ELF). She explains how even “moderate” alcohol can accelerate fibrosis when metabolic risks are present, why PEth biomarker testing helps uncover under-reported use, and how to triage patients who land in the F3–F4 range. Practical takeaways include culturally sensitive Mediterranean-style nutrition, 5–10% weight-loss goals, tailored exercise, alcohol cessation, and when to consider resmetirom (Rezdiffra) for eligible F2–F3 non-cirrhotic patients. The talk also covers HCC surveillance (and when to prefer CT/MRI over ultrasound in central adiposity) and sets clear pathways for primary care, GI, and hepatology to work in sync.
Watch Now
Webcast: MASLD Pharmacotherapy With Chantil Jeffreys
September 2025
In this MASLD Community Network webcast, Chantil Jeffreys, FNP, walks through a practical framework for pharmacotherapy in MASLD/MASH—from lifestyle-first approaches to the evolving role of GLP-1 receptor agonists and bariatric/endoscopic options. She clarifies common misconceptions (e.g., statins are safe—and beneficial—for patients with fatty liver), reviews evidence and real-world considerations for vitamin E and pioglitazone, and explains where resmetirom (Rezdiffra) fits today for non-cirrhotic MASH with F2–F3 fibrosis—including monitoring, drug–drug interactions, and documentation tips that support payer approval. The session also covers cardiovascular risk reduction, peri-procedure guidance for GLP-1s, and practical strategies for staging and follow-up so clinicians can confidently personalize therapy and improve outcomes.
Watch Now
Webcast: Comparing F3 and F4 Fibrosis With Anna Marie Hefner & Renee Pozza
November 2025
Join Anna Marie Hefner, RN and Renee Pozza, FNP-BC from Southern California Liver & GI Centers for a practical, case-based deep dive into advanced MASLD/MASH—what F3 vs F4 (cirrhosis) really means for staging, treatment, and surveillance. Using a 55-year-old patient scenario, they walk through interpreting FIB-4, FibroScan® (kPa + CAP), ELF, and routine labs; when to add ultrasound + AFP for HCC surveillance, and when to scope for esophageal varices. You’ll hear how they structure follow-up (from biweekly check-ins early to every 3 months), tailor diet and exercise to real-world habits, incorporate GLP-1s for weight and metabolic control, and consider resmetirom for eligible F2–F3 patients (not F4). The session also covers when to escalate to colonoscopy for alternative bleeding sources, and how to alternate US with triphasic CT/MRI in high-risk patients. Perfect for GI/hepatology APPs looking for a clear, actionable framework to manage fibrosis progression and optimize outcomes.
Watch Now
Live From GHAPP National: MASH: The Latest and Greatest of Management
November 2025
In this expert-led session, Allysa Saggese, NP, at Weill Cornell Medicine, breaks down the latest evidence and evolving best practices in the diagnosis and management of MASLD and MASH. She explains the 2023 nomenclature changes, the full spectrum of steatotic liver disease, and how metabolic dysfunction drives both MASLD and inflammatory MASH. Allysa reviews practical diagnostic pathways—including non-invasive tests like FIB-4, ELF, FibroScan, and elastography—and highlights why MASLD/MASH should always be evaluated in the broader context of metabolic disorders such as diabetes, obesity, and dyslipidemia. She also outlines the foundation of lifestyle-based treatment, offering real-world communication strategies to help patients succeed with diet, activity, and weight management goals. The talk covers major therapeutic advances, including the first FDA-approved MASH therapy, resmetirom (a THR-β agonist), as well as the growing role of GLP-1 receptor agonists like semaglutide in improving metabolic drivers of liver inflammation and fibrosis. Allysa discusses dosing, titration, safety considerations, expected side effects, and what clinicians should know when co-managing cardiometabolic conditions. She closes with insights on future MASH drug development, combination therapy approaches, and practical pearls for supporting patients through a chronic, complex liver disease.
Watch Now
Webcast: MASLD Pharmacotherapy With Lisa Richards
August 2025
Join Lisa Richards from UC San Diego Health, for a comprehensive overview of MASLD Pharmacotherapy as part of the GHAPP MASLD Community Network, proudly sponsored by Madrigal Pharmaceuticals. This educational session explores the evolving treatment landscape for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and MASH (Metabolic Dysfunction-Associated Steatohepatitis), including the shift from exclusive reliance on lifestyle interventions and comorbidity optimization to the introduction of targeted pharmacologic therapies. Lisa reviews the role of GLP-1 receptor agonists, such as semaglutide, and the ESSENCE trial results demonstrating significant improvements in MASH and liver fibrosis. She also outlines the clinical considerations and limitations of legacy treatments like vitamin E and pioglitazone, based on data from the PIVENS trial. The highlight of the session is a detailed exploration of resmetirom (Rezdiffra)—the first FDA-approved therapy for non-cirrhotic NASH with moderate to advanced fibrosis (F2–F3). Lisa reviews key findings from the MAESTRO-NASH trial, including improvements in fibrosis and MASH resolution, and discusses real-world implementation strategies, including non-invasive monitoring tools (FibroScan, ELF, MRI-PDFF), statin dose adjustments, and managing drug–drug interactions. This session equips hepatology and GI providers with the tools to personalize MASH care, navigate insurance and safety considerations, and deliver cutting-edge, evidence-based treatment to patients with MASLD.
Watch Now
Live From GHAPP National: MASH: The Latest and Greatest of Management
November 2025
In this expert-led session, Allysa Saggese, NP, at Weill Cornell Medicine, breaks down the latest evidence and evolving best practices in the diagnosis and management of MASLD and MASH. She explains the 2023 nomenclature changes, the full spectrum of steatotic liver disease, and how metabolic dysfunction drives both MASLD and inflammatory MASH. Allysa reviews practical diagnostic pathways—including non-invasive tests like FIB-4, ELF, FibroScan, and elastography—and highlights why MASLD/MASH should always be evaluated in the broader context of metabolic disorders such as diabetes, obesity, and dyslipidemia. She also outlines the foundation of lifestyle-based treatment, offering real-world communication strategies to help patients succeed with diet, activity, and weight management goals. The talk covers major therapeutic advances, including the first FDA-approved MASH therapy, resmetirom (a THR-β agonist), as well as the growing role of GLP-1 receptor agonists like semaglutide in improving metabolic drivers of liver inflammation and fibrosis. Allysa discusses dosing, titration, safety considerations, expected side effects, and what clinicians should know when co-managing cardiometabolic conditions. She closes with insights on future MASH drug development, combination therapy approaches, and practical pearls for supporting patients through a chronic, complex liver disease.
Watch Now
Webcast: MASLD Basics With Scott Springer
August 2025
Welcome to the GHAPP MASLD Community Network, where Scott Springer, PA-C, from Erie County Medical Center in Buffalo, NY, provides a comprehensive overview of the evolving landscape of steatotic liver disease. Sponsored by Madrigal Pharmaceuticals, this session breaks down the recent nomenclature shift from NAFLD/NASH to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and MASH (Metabolic Dysfunction-Associated Steatohepatitis). Scott explores how overlapping etiologies like alcohol-associated liver disease (ALD) and the emerging classification of MetALD better reflect real-world patient populations. Learn about key diagnostic strategies—including the use of FIB-4, ELF score, and transient elastography—to assess fibrosis risk and guide referral to hepatology care. With a clinical case study, Scott highlights the importance of accurate staging, ruling out alternative etiologies, and understanding progression rates in high-risk patients. This session is a must-watch for GI and hepatology APPs looking to stay updated on guidelines, non-invasive diagnostics, and best practices for managing MASLD/MASH in primary and specialty settings.
Watch Now
Webcast: Comparing F3 and F4 Fibrosis With Allysa Saggese
September 2025
In this session from the MASLD/MASH Community Network, Allysa Saggese, NP from Weill Cornell Medicine in New York, explores the critical differences between F3 and F4 fibrosis through two detailed case studies. Accurate staging is essential in fatty liver disease management, as it directly impacts treatment decisions, eligibility for FDA-approved therapies like resmetirom, and the need for hepatocellular carcinoma (HCC) surveillance. Allysa explains how non-invasive tests such as FIB-4, FibroScan, ELF, CAP, and MRI elastography compare, when to consider a liver biopsy, and how to interpret discordant results. She also discusses treatment pathways, the role of GLP-1 receptor agonists, lifestyle modification, and monitoring strategies for patients with advanced fibrosis versus cirrhosis. This practical overview provides clinicians with a clear framework to distinguish between F3 and F4, ensuring patients receive timely interventions, surveillance, and education to improve long-term outcomes in MASLD/MASH.
Watch Now
Webcast: MASLD Pharmacotherapy With Melissa Franco
September 2025
In this session from the MASLD Community Network, Melissa Franco, PA from the University of Miami, provides a comprehensive overview of pharmacotherapy for MASLD and MASH. She reviews the role of lifestyle interventions such as the Mediterranean diet, weight loss, and exercise while highlighting the importance of controlling metabolic and cardiovascular risk factors including diabetes, hypertension, and dyslipidemia. Melissa discusses pharmacologic options including GLP-1 receptor agonists like semaglutide, which have shown promise in improving both weight loss and liver histology, as well as the evolving roles of vitamin E, pioglitazone, and resmetirom (Rezdiffra)—the first FDA-approved therapy for non-cirrhotic MASH with stage 2–3 fibrosis. Practical considerations, safety profiles, drug-drug interactions, and monitoring strategies are explained, giving clinicians a clear framework for managing patients with fatty liver disease. This session emphasizes why a combination of lifestyle changes, risk factor control, and emerging pharmacologic therapies are critical for improving outcomes in MASLD and MASH.
Watch Now
Webcast: MASLD Pharmacotherapy With Elizabeth Alqueza
August 2025
In this presentation, Elizabeth Alqueza, PA-C at Beth Israel Deaconess Medical Center, provides a comprehensive overview of pharmacotherapy for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and MASH. She highlights the latest treatment strategies, including lifestyle modifications, cardiovascular risk reduction, and targeted liver-directed therapies. Elizabeth reviews the role of GLP-1 receptor agonists in weight loss and liver health, the evidence for Vitamin E and Pioglitazone in select patients, and the landmark approval of Resmetirom (Rezdiffra)—the first FDA-approved therapy for MASH with moderate to advanced fibrosis. Drawing from clinical trial data, including the MAESTRO-NASH trial, she explains mechanisms of action, efficacy outcomes, safety considerations, and practical prescribing guidance. This session underscores the importance of combining non-invasive testing, lifestyle interventions, and emerging pharmacologic therapies to improve patient outcomes and prevent progression to cirrhosis and liver-related complications.
Watch Now